ABSTRACT
Reduction in circuit prime during cardiopulmonary bypass has benefits for the patient with a low body surface area, anemia, patient refusal to receive blood products, and aids the practitioner's goal to minimize exposure to blood products. Described here is a simple, low-cost technique that has been shown to decrease priming volume in any bypass circuit and allow a significant increase in 'on bypass hemoglobin'.
Subject(s)
Blood Component Transfusion , Blood Transfusion, Autologous , Cardiac Surgical Procedures , Cardiopulmonary Bypass , Hemodilution , Blood Transfusion, Autologous/instrumentation , Blood Transfusion, Autologous/methods , Hematocrit , Hemoglobins , HumansABSTRACT
Three available methods used to determine heparin loading dose were studied to determine the most reliable method for reaching a target pre-bypass activated clotting time (ACT) of 510 seconds. One hundred and seven patients were randomly assigned to one of three treatment methods: A) 300 units/kg; B) Hemostasis Management System (HMS); C) RX/DX. Five different lots of heparin were assigned to Groups A and B, and Group C had one heparin lot. Different lots were used to account for possible variations in heparin activity. Post-skin incision ACTs, post-heparin pre-bypass ACTs, and heparin loading doses were compared. The mean and standard deviation of the post-heparin pre-bypass ACTs were used to determine which method was most reliable to obtain a desired ACT. There was no statistical difference between different heparin lots. There was no difference in the post-heparin ACTs for the three methods (A:487 +/- 135 vs. B:474 +/- 105 vs. C:474 +/- 111 sec). There was a statistically significant difference between the standard deviation for the HMS and 300 u/kg standard deviations (p < 0.05). The HMS has the smallest deviation which makes it the most reliable predictor of heparin loading doses to reach a target ACT for cardiopulmonary bypass.
